Stevens-Johnson syndrome associated with daclatasvir and sofosbuvir co-therapy in hepatitis C treatment: a rare case report.

Background: Stevens-Johnson syndrome (SJS) is an uncommon, severe skin and mucous membrane illness that is frequently triggered by some medications and infections like herpes simplex virus infection or Mycoplasma pneumoniae infection. Case presentation: This case report describes an uncommon but severe side effect that happened after taking two antiviral medications, sofosbuvir and daclatasvir, to treat hepatitis C virus infection. A 54-year-old man developed mild rash after taking prescribed medications for 3 days, which rapidly progressed to typical SJS with significant mucosal and skin involvement. With passing days, the patient's condition kept on getting worse despite conservative care and cessation of sofosbuvir and daclatasvir. The patient was given continuous supportive and symptomatic treatment, but despite of intensive care, the patient expired on fourth day of hospital admission. Discussion: "Daclatasvir and Sofosbuvir Co-therapy" is considered an effective regime for Hepatitis C (Hep C) infection; however, we have a rare occurrence of SJS due to this drug regime that has not been reported in literature previously. By presenting this case, we hope to offer valuable insights that will help clinicians in the identification and management of similar cases ensuring patient safety while maintaining the benefits of this effective regime. Conclusion: Even though SJS is rare, the possibility that it might have occurred due to sofosbuvir-daclatasvir highlights the need for clinicians to be vigilant while prescribing this regime and educate the patients about the signs and symptoms of SJS. Clinical practices can lower hazards and improve patient safety by implementing these measures.